Osteo-Fluidic-Sensitive (OFS) method for frequent tension-type headache
Official title: Evaluation of the Efficacy of the Osteo-Fluidic-sensitive (OFS) Versus Placebo Method in the Management of Frequent Episodic Tension-type Headache. Pilot Study.
Run by Poitiers University Hospital · NCT05229224 · Data updated 2026-11-12
This study will test whether the Osteo-Fluidic-Sensitive (OFS) method can reduce the number of headache days per month in adults with frequent episodic tension-type headache.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Poitiers University Hospital Academic / other |
| Locations | 1 site (Poitiers) |
| Status | Recruiting |
| Started | November 29, 2022 |
| Main results expected | May 29, 2026 |
| Study ends | August 29, 2026 |
| Registry record updated | January 6, 2026 |
| Trial ID | NCT05229224 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–75 years old with highly frequent episodic tension-type headache (2–14 headache days per month) who completed a headache diary and can give informed consent are ideal candidates.
✕Probably not a fit
People with chronic tension-type headache, migraine-only disorders, cluster headaches, neuralgias, those on excluded medications (e.g., venlafaxine, gabapentin, duloxetine, clomipramine, botulinum toxin), pregnant or breastfeeding women, and those unable to attend the center are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with frequent episodic tension-type headache (2–14 days per month) will be enrolled at CHU Poitiers and receive either the OFS method or a placebo (sham) procedure. Participants will complete a headache diary before and during the 3-month treatment period to measure change in the number of headache days per month. Secondary outcomes include quality of life measures and use of rescue medications. The trial is a pilot, single-center, placebo-controlled interventional comparison to estimate effect size and feasibility.
Why it matters
Potential benefit: If effective, OFS could reduce monthly headache days, improve quality of life, and lower the need for acute headache medications.
How similar studies have gone: This specific OFS method appears novel and has not been widely tested in controlled trials, while related manual and osteopathic approaches have produced mixed results in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 and 75 years' old * Person having highly frequent episodic tension type headache (between 2 and 14 days of headaches per month) associated or not to headache with characteristic of a migraine per International Classification of Headache Disorders 3rd edition criteria * Person who completed his headache agenda the month before the study. * Patient who understands and accepts the effects of the study * Signed consent * Person with health insurance coverage Exclusion Criteria: * Person having secondary or primary headaches (chronic tension type headache, migraines only, Cluster headaches, Neuralgias ...) * Person on treatment of venlafaxine, gabapentine, duloxetine, clomipramine et toxine botulique. * Concomitant participation to another clinical research * Pregnant or lactating women, women of child-bearing age who do not have effective contraception. * People with reinforced protection (juvenile), people deprived of liberty per justice or administrative decision, people living in a sanitary and social establishment, adults under legal protection and people in critical medical conditions
Where it's running
-
CHU Poitiers
Poitiers, France Recruiting
Study contacts
- Principal investigator: Helene KERSUZAN — CHU de Poitiers FRANCE
- Study coordinator: Helene KERSUZAN
- Email: helene.kersuzan@chu-poitiers.fr
- Phone: +33549443961
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Left Bundle Branch Area Pacing to Preserve Heart Function in Atrial Fibrillation
In adults with permanent atrial fibrillation and preserved heart pumping, this study tests whether left bundle branch area pacing helps the heart work better than standard right ventricular pacing.
-
See if video telemedicine with a caller’s mobile camera improves care for adults with acute dyspnea
This study tests whether adding video calls from a caller’s mobile phone to the emergency dispatch process helps improve care for adults with acute shortness of breath.
-
Personalized Night-time Nursing to Improve Sleep in Critically Ill Patients
This study tests whether sleep-guided nursing, aided by a sleep-monitoring device, can improve sleep quality for adults in the ICU and whether that helps their prognosis.
-
HeartLogic-guided remote heart failure follow-up for adults with an implanted HeartLogic-enabled ICD/CRT-D
In adults with heart failure and a HeartLogic-enabled implant, this study tests whether remote monitoring guided by HeartLogic helps reduce death, unplanned heart failure hospitalizations, or drops in quality of life within 12 months compared with standard in-person follow-up.
-
Dangerous heart rhythms after a heart attack
This study will see how survival and treatment differ for adults who develop sustained ventricular tachycardia or ventricular fibrillation during a heart attack, comparing events that occur within 48 hours to those that occur later.
-
Is preoperative urine culture before TURB necessary for preventing fever UTIs?
This trial tests whether skipping the preoperative urine culture before TURB is as safe as doing it, by comparing febrile urinary tract infections in the 30 days after surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.